

The Doctoral Program **ION CHANNELS AND TRANSPORTERS AS MOLECULAR DRUG TARGETS** („MolTag“) is pleased to invite you to the following lecture

# Novel Strategies for Atrial Fibrillation

by **Sridharan RAJAMANI, PhD**

Principal Scientist at Amgen, San Francisco, USA

on: **Tuesday, Sept 3<sup>rd</sup>, 2019, 16:00**

at: **UZA2, Althanstr. 14, 1090 Vienna; Pharmacy Building, Room 2D 358**



## CURRICULUM VITAE

### Education

- 1999** Ph.D. Pharmacology & Toxicology, University of Vienna, Austria
- 1996** Master of Pharmacy in Pharmacology & Toxicology
- 1993** Bachelor of Pharmacy, The Tamilnadu Dr. MGR Medical University, India

### Research Experience

- 2015 – Present** Cardiometabolic Disorders, **Amgen Inc**
- 2009 – 2015** Cardiovascular Biology, **Gilead Sciences, CA**
- 2005 – 2009** Department of Pharmacological Sciences, **CV Therapeutics Inc, Palo Alto, CA**
- 1999 – 2004** Department of Medicine, **University of Wisconsin-Madison, WI**

**Society memberships:** 1999 - Present Biophysical Society , 2001 - Present Cardiac Electrophysiological Society; 2002 - Present American Heart Association; 2006 – Present: Heart Rhythm Society; 2007 – Present European Society of Cardiology;

**Professional Honors:** 2017 Invited member of the Board of Examiners, University Medical Center, Utrecht, The Netherlands; 2006 – Present Invited member of the Board of Examiners, The Tamilnadu Dr. MGR Medical University, India; 2000 – 2002 Post-doctoral fellowship training grant from the American Heart Association (Wisconsin/Northland affiliate); 1996 – 1999 Recipient of Fellowship from Austrian Academic Exchange Service, Federal Ministry of Research and Science, Republic of Austria for the doctoral program;

**Contact:** Doctoral Program MolTag, Pharmacoinformatics Research Group, University of Vienna; <http://moltag.univie.ac.at/>, [Office.moltag@univie.ac.at](mailto:Office.moltag@univie.ac.at), phone: 01 4277 55320